Hadassah

Hadassah Clinical Trial Reveals Safety and Efficacy of Stem Cell Technology in Treating ALS

Wednesday, Feb 15 2012

"This may represent the biggest hope in the field of degenerative diseases like ALS," Prof. Dimitrios Karussis, head of the Hadassah University Medical Center's Multiple Sclerosis Center, said about the clinical trial just completed at Hadassah where stem cells were used to treat Amyotrophic Lateral Sclerosis (ALS).

Even though this was a trial to determine the safety of the technology, early clinical follow up of the patients demonstrated an improvement in breathing and swallowing ability as well as in muscular power. "I am very excited about the safety results, as well as the indications of efficacy," Prof. Karussis said. The initial patients who were treated with BrainStorm Cell Therapeutics' NurOwn™ stem cell technology experienced no significant side effects in this Phase I/II clinical trial. As a result, Hadassah's ethics and safety committee has now granted BrainStorm approval to proceed with treating additional patients.

NurOwn™ technology processes adult human stem cells that are present in bone marrow and are capable of self-renewal and differentiation into many other cell types. A progressive neurodegenerative disease, ALS, often referred to as Lou Gehrig's disease, affects nerve cells in the brain and the spinal cord. With this technology, the bone marrow cells are induced to differentiate into cells capable of releasing neurotrophic factors which can help ALS patients. According to the ALS Association, approximately 5,600 people in the United States are diagnosed with ALS each year and it is estimated that as many as 30,000 Americans may have the disease at any given time.

The study, led by Prof. Karussis, is being conducted in conjunction with a scientific team from BrainStorm.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Jun 20 2017

Send in the Clowns: A Hadassah UK Dispatch

This week Hadassah UK (HUK) brought in one of the Hadassah Medical Organization's best and more unusual, head medical clown David Barashi (DuSH).

READ MORE ›
alt_text

Friday, Jun 16 2017

Hadassah’s Director General Receives Honorary PhD from Cyprus Medical School

For sharing his knowledge and experience with senior officials in the Cyprus medical system, Prof. Zeev Rotstein, Director General of the Hadassah Medical Organization, was awarded an honorary PhD from the St. George University of London’s Medical Program at the University of Nicosia Medical School in Cyprus.

READ MORE ›
alt_text

Thursday, Jun 8 2017

Hadassah Doctors Discover Bullet
in 12-Year-Old’s Arm

Muhammad Baduan, age 12, had been experiencing pain in his arm on and off for months. Hadassah Hospital Ein Kerem Emergency Room physicians put an end to the boy’s pain when they solved the mystery: Muhammad had a 22-millimeter bullet hidden in that arm--a bullet that had been shot into the air as part of a post-wedding ceremony celebration.

READ MORE ›
alt_text

Monday, Jun 5 2017

Hadassah Cutting-Edge Neuropsychiatrist Keynotes Alzheimer’s Conference

“The key is to give medicines much earlier--before the brain material has been destroyed by Alzheimer’s disease,” Dr. Shahar Arzy, head of the Hadassah Medical Organization’s Computational Neuropsychiatry Laboratory, told his audience at the Alzheimer’s Foundation of America (AFA)’s New York Educational Conference on May 5, 2017.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More